Autres langues Mind Medicine (MindMed) Inc.

Actions

MNMD

CA60255C8850

Temps réel estimé Cboe BZX Autres places de cotation 21:17:42 06/06/2024			Varia. 5j.	Varia. 1 janv.
7,075 ^USD	-4,65 %		-18,22 %	+96,86 %

05/06	Le secteur des soins de santé est stable en début de séance.	MT
05/06	Les actions de Mind Medicine chutent après que le comité de la FDA ait voté contre le médicament psychédélique de Lykos Therapeutics	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

MindMed ICPR 2024: Rapid and Durable Response to a Single Dose of MM120 (Lysergide) in Generalized Anxiety Disorder: A Dose-Optimization Study	14:08
Sector Update: Health Care Stocks Steady Premarket Wednesday	05/06
Mind Medicine Shares Fall After FDA Committee Votes Against Lykos Therapeutics' Psychedelic Drug	05/06
Top Premarket Decliners	05/06
MindMed to Participate in June Conferences	28/05
Mind Medicine (MindMed) Inc. - New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting Show Growing Burden and Impact of Generalized Anxiety Disorder in the US	10/05
MindMed to Participate at May Investor Conferences	09/05
New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US	09/05
Mind Medicine Inc. Announces the Departure of Schond Greenway as Chief Financial Officer	08/05
MindMed Reports First Quarter 2024 Financial Results and Business Updates	08/05
Mind Medicine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
MindMed ISPOR 2024: Work Productivity and Activity Impairment Associated with Generalized Anxiety Disorder among Adults in the United States	06/05
MindMed ISPOR 2024: Health-related Quality of Life Associated with Generalized Anxiety Disorder among Adults in the United States	06/05
MindMed ISPOR 2024: Health Care Resource Use Associated with Generalized Anxiety Disorder among Adults in the United States	06/05
MindMed APA 2024: Screening Adults in the US General Population to Detect Cases of Undiagnosed Generalized Anxiety Disorder	04/05
MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York	04/05
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update	02/05
MindMed to Present at Upcoming May Medical Conferences	25/04
MindMed to Present at Upcoming April Medical Conferences	02/04
MindMed Announces Voluntary Delisting from Cboe Canada	01/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Mind Medicine (MindMed) Inc.

Actions

MNMD

CA60255C8850

Autres langues

Filtres